We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Surface Ophthalmics

News List

Harrow Health Announces Closing of $20 Million Aggregate Principal Amount Offering of 8.625% Senior Notes Due 2026 firstwordpharma
June 18, 2021
Harrow Health, Inc. an ophthalmic-focused healthcare company, today announced the closing of its underwritten registered public offering of $20 million aggregate principal amount of 8.625% senior notes due 2026 (the "Notes")
Surface Ophthalmics Announces First Patient Dosed in SURF-200 Trial for Acute Dry Eye americanpharmaceuticalreview
February 10, 2021
Surface Ophthalmics announced the first patient has been dosed in the Phase II clinical trial for its investigational product SURF-200 (betamethasone in Klarity® vehicle) for the treatment of acute dry eye.